News Search Results
Sep 08, 2026, 06:01 ET 페프로민 바이오, 기존 CD19 CAR T세포 치료 실패 포함 재발성/불응성 B세포 림프종에서 깊고 지속적인 완전관해 입증한 제1상 임상시험 결과 랜싯에 게재 발표
확대됐다. 결과는 또한 확장 단계에서 치료받은 첫 번째 환자도 최초 질병 평가에서 완전관해에 도달했다고 보고했다. 이 환자는 CD19 표적 CAR T세포 치료 후 질환이 진행된 삼중 유전자이상 고도 B세포 림프종(triple-hit high-grade B-cell lymphoma) 환자였다.페프로민 바이오의 과학 부문 창립자인 래리 W. 곽(Larry W. Kwak) 의학박사는 "동료 심사를 거친 이번 데이터가 랜싯에 게재된 것은 이 새로운 요법의 중요성을 인정받은 의미 있는 성과"라며 "재발 사례가 전혀 없다는 점을 고려할
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
Koordinationszentrum und Produktionsstandort sowie bei der Patientenrekrutierung unterstützen."Im Dezember 2024 stellte das Institute for Follicular Lymphoma Innovation (IFLI) bis zu 11 Millionen US-Dollar zur Unterstützung der klinischen Entwicklung von PMB-CT01 bei Patienten mit rezidiviertem oder refraktärem
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19
centre de coordination et site de fabrication, en plus de se charger du recrutement des patients. »En décembre 2024, l'Institute for Follicular Lymphoma Innovation (IFLI) s'est engagé à verser jusqu'à 11 millions de dollars pour soutenir le développement clinique du PMB-CT01 chez les patients atteints
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 04, 2026, 08:30 ET Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments
begin in blood-forming tissue, such as bone marrow, or in cells of the immune system. There are over 100 types of blood cancers, including leukemia, lymphoma and myeloma.
More news about: Alexandria Real Estate Equities, Inc.
Sep 03, 2026, 11:30 ET CHICAGO WHITE SOX, CIBC AND LOCAL NONPROFITS UNITE FOR CHILDHOOD CANCER AWARENESS DAY ON SEPTEMBER 6
Melanie's neurosurgeon Dr. Dimitrios Nikas and 16-year-old Arlington Heights native Logan C., who is currently battling Non-Hodgkin Lymphoma, are scheduled to deliver the game's ceremonial first pitches. Game Ball Delivery – The White Sox will honor
More news about: CIBC
Sep 03, 2026, 07:15 ET ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Sep 01, 2026, 10:01 ET Blood Cancer Treatment Advances Have Saved Nearly 26 Million Years of Life Over Past 75 Years
Substantial improvement in Hodgkin lymphoma and acute lymphoblastic leukemia treatment began decades ago, leading to the largest cumulative life-years saved to this point (about 32% of the total life-years saved is for Hodgkin lymphoma and 25% for acute lymphoblastic leukemia).Non-Hodgkin
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Sep 01, 2026, 09:57 ET Unleashed Brands Foundation and Urban Air Adventure Park Launch 2026 'Sock It to Cancer' Campaign
Blood Cancer United (formerly The Leukemia & Lymphoma Society) to "
More news about: Unleashed Brands
Sep 01, 2026, 09:54 ET From sketchbook to speedway: One child's dream drives hope for kids with blood cancer
subsidiaries, registered in various countries.About Blood Cancer United®Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: Valvoline Global Operations
Sep 01, 2026, 08:30 ET Lymphoma Research Foundation Announces International T-Cell Lymphomas Consortium
https://lymphoma.org/About the Lymphoma Research Foundation:The Foundation is the nation's largest nonprofit organization devoted exclusively to funding innovative lymphoma research and serving those who have had lymphoma and the health care providers, family and friends who help care for lymphoma patients.
More news about: Lymphoma Research Foundation
Sep 01, 2026, 07:30 ET Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:15 ET Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Aug 31, 2026, 17:58 ET Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Aug 28, 2026, 07:30 ET Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:09 ET Kazia Therapeutics Limited Announces Proposed Public Offering
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Aug 26, 2026, 09:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
use.First Half Revenue Growth: Reported $1.4M of revenue in the first half of 2026, representing a 112% increase year-over-year.Feline Lymphoma Manuscript Submission: Submitted for publication the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated
More news about: VolitionRx Limited
Aug 25, 2026, 11:00 ET Blood Cancer United Launches 2026 Light The Night Season During Blood Cancer Awareness Month
WASHINGTON, Aug. 25, 2026 /PRNewswire/ -- Blood Cancer United, formerly The Leukemia & Lymphoma Society (LLS), the largest global nonprofit focused on serving blood cancer patients, is launching its signature community event,
More news about: BLOOD CANCER UNITED, INC.
Aug 21, 2026, 08:00 ET Kurt Arnold, Jason Itkin Named 2027 "Lawyer of the Year" as 12 Arnold & Itkin Attorneys Earn Best Lawyers® Recognition
against Bayer/Monsanto over the weed killer Roundup, the firm has secured a string of record verdicts on behalf of clients who developed non-Hodgkin's lymphoma, including a $2.25 billion verdict in Philadelphia in January 2024 and a $2.065 billion verdict in Georgia in March 2025. The latter is the largest
More news about: Arnold & Itkin LLP
Aug 21, 2026, 04:03 ET Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
for the treatment of NSCLC with EGFR exon20ins. Golidocitinib is approved in China for the treatment of relapsed and refractory peripheral T cell lymphoma. Birelentinib, a BBB-penetrant LYN/BTK dual inhibhitor, is currently in pivotal studies for various hematological diseases. DZD6008, a 4th
More news about: Dizal Pharmaceutical
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
tumors, including melanoma, urothelial, colorectal, ovarian, pancreatic, and lung cancers, as well as hematologic malignancies such as leukemia and lymphoma. BTN3A is also present on innate and adaptive immune cells, including γδ T cells, NK cells, T cells, and B cells, and plays a pivotal role in initiating
More news about: DelveInsight Business Research, LLP
Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results
refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL) have been initiated. In August 2026, the IND clearance was achieved from NMPA in China for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard
More news about: CARsgen Therapeutics
Aug 17, 2026, 10:30 ET Cancer Diagnostics Market worth $44.92 billion by 2031 - Exclusive Report by MarketsandMarkets™
minimal residual disease testing. Foresight's PhasED-Seq technology enhances Natera's solid-tumor MRD capabilities and supports its expansion into lymphoma monitoring.Company Revenue Share DetailsThe top five players in the global cancer diagnostics
More news about: MarketsandMarkets
Aug 17, 2026, 08:00 ET OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
hematologic malignancies, including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, ovarian cancer, glioblastoma, and mantle cell lymphoma, which supports the potential of ONC-783 as a treatment across multiple tumor types. In addition, a subcutaneous formulation was developed for ONC-783
More news about: OncoC4
Aug 16, 2026, 20:00 ET AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma
known as Prizloncabtagene Autoleucel (Prizlon-cel), an anti-CD20/CD19 bispecific CAR-T, for the treatment of relapsed or refractory (r/r) Large B-cell Lymphoma (LBCL).
More news about: AbelZeta Pharma, Inc.